The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breastfeeding is being studied as a means to prevent transmission by reducing HIV-1 viral load in the maternal serum and breast milk. Studies characterizing the exposure of antiretroviral agents in breast milk and in the breastfed infant are important to understand the dynamics of HIV-1 replication in breast milk and to establish the safety profiles of antiretroviral drugs.
References
1.
NduatiR., JohnG., Mbori-NgachaD.Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA2000; 283: 1167–1174.
2.
Breastfeeding and HIV International Transmission Study Group.Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis2004; 189: 2154–2166.
3.
ScarlattiG.Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev2004; 6: 67–78.
4.
ValeaD., TuaillonE., Al TabaaY.CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology2011; 8: 34.
5.
JohnG.C., NduatiR.W., Mbori-NgachaD.A.Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis2001; 183: 206–212.
6.
PillayK., CoutsoudisA., YorkD.Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr2000; 24: 330–336.
7.
RichardsonB.A., John-StewartG.C., HughesJ.P.Breast-milk infectivity in human immunodeficiency virus type1-infected mothers. J Infect Dis2003; 187: 736–740.
8.
RousseauC.M., NduatiR.W., RichardsonB.A.Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis2004; 190: 1880–1888.
9.
SembaR.D., KumwendaN., HooverD.R.Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis1999; 180: 93–98.
10.
ShapiroR.L., Ndung'uT., LockmanS.Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis2005; 192: 713–719.
11.
Van de PerreP.Mother-to-child transmission of HIV-1: the ‘all mucosal’ hypothesis as a predominant mechanism of transmission. AIDS1999; 13: 1133–1138.
12.
KoulinskaI.N., VillamorE., ChaplinB.Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J ‘Acquir Immune Defic Syndr2006; 41: 93–99.
13.
John-StewartG., Mbori-NgachaD., EkpiniR.Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr2004; 35: 196–202.
14.
WHO/UNAIDS/UNICEF.Progress report 2011: Global HIV/AIDS response. Epidemic update and health sector progress towards universal access (Updated 30 November 2011. Accessed 14 May 2012.) Available from www.who.int/hiv/pub/progress_report2011/en/index.html.
15.
ManigartO., CrepinM., LeroyV.Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission. J Infect Dis2004; 190: 1422–1428.
16.
LehmanD.A., ChungM.H., John-StewartG.C.HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS2008; 22: 1475–1485.
17.
BecquartP., PetitjeanG., TabaaY.A.Detection of a large T-cell reservoir able to replicate HIV-1 actively in breast milk. AIDS2006; 20: 1453–1455.
18.
PalombiL., PirilloM.F., AndreottiM.Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther2012; in press.
19.
RezkN.L., WhiteN., BridgesA.Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit2008; 30: 611–619.
20.
CorbettA., MartinsonF., RezkN.Lopinavir/ritonavir concentrations in breast milk and breast-feeding infants.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, Canada. Abstract 947.
21.
ShapiroR.L., HollandD.T., CapparelliE.Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis2005; 192: 720–727.
22.
MirochnickM., ThomasT., CapparelliE.Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother2009; 53: 1170–1176.
23.
SchneiderS., PeltierA., GrasA.Efavirenz in human breast milk, mothers’, and newborns’ plasma. J Acquir Immune Defic Syndr2008; 48: 450–454.
24.
ColebundersR., HodossyB., BurgerD.The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS2005; 19: 1912–1915.
25.
CorbettA., KashubaA., RezkN.Antiretroviral drug concentrations in breast milk and breastfeeding infants.15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 648.
26.
WeidleP.J., ZehC., MartinA.Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breastfeeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother2011; 55: 5168–5171.
27.
SpencerL., NeelyM., MordwinkinN.Intensive pharmacokinetics of zidovudine, lamivudine, and atazanavir and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, Canada. Abstract 942.
28.
ItoS., LeeA.Drug excretion into breast milk – overview. Adv Drug Deliv Rev2003; 55: 617–627.
29.
JonkerJ.W., MerinoG., MustersS.The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med2005; 11: 127–129.
30.
VlamingM.L.H., LagasJ.S., SchinkelA.H.Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev2009; 61: 14–25.
31.
WeissJ., RoseJ., StorchC.H.Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother2007; 59: 238–245.
32.
ZehC., WeidleP.J., NafisaL.HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single arm trial of triple antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med2011; 8: e1000430.
33.
La PorteC.J.L., BackD.J., BlaschkeT.Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy2006; 3: 4–14.
34.
MofensonL.M.Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther2010; 15: 537–553.
35.
SlykerJ.A., ChungM.H., LehmanD.A.Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS ONE2012; 7: e29777.
36.
PowisK.M., KitchD., OgwuA.Increased risk of preterm delivery among HIV infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis2011; 204: 506–514.
